

Institut luxembourgeois de la normalisation de l'accréditation, de la sécurité et qualité des produits et services

**ILNAS-EN 14683:2019** 

# Medical face masks - Requirements and test methods

Medizinische Gesichtsmasken -Anforderungen und Prüfverfahren

Masques à usage médical - Exigences et méthodes d'essai

#### **National Foreword**

This European Standard EN 14683:2019 was adopted as Luxembourgish Standard ILNAS-EN 14683:2019.

Every interested party, which is member of an organization based in Luxembourg, can participate for FREE in the development of Luxembourgish (ILNAS), European (CEN, CENELEC) and International (ISO, IEC) standards:

- Participate in the design of standards
- Foresee future developments
- Participate in technical committee meetings

https://portail-qualite.public.lu/fr/normes-normalisation/participer-normalisation.html

#### THIS PUBLICATION IS COPYRIGHT PROTECTED

Nothing from this publication may be reproduced or utilized in any form or by any mean - electronic, mechanical, photocopying or any other data carries without prior permission!

# EUROPEAN STANDARD ILNAS-EN 14683:2019**EN 14683**

# NORME EUROPÉENNE EUROPÄISCHE NORM

March 2019

ICS 11.140

Supersedes EN 14683:2014

#### **English Version**

# Medical face masks - Requirements and test methods

Masques à usage médical - Exigences et méthodes d'essai

Medizinische Gesichtsmasken - Anforderungen und Prüfverfahren

This European Standard was approved by CEN on 19 November 2018.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Former Yugoslav Republic of Macedonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION COMITÉ EUROPÉEN DE NORMALISATION EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

	Europ	ean foreword	
	Introduction		
	1	Scope	
	2	Normative references	
	3	Terms and definitions	
	4	Classification	
- Preview only Copy via ILNAS e-Shop	5 5.1 5.1.1 5.1.2 5.2 5.2.1 5.2.2 5.2.3 5.2.4 5.2.5 5.2.6	Requirements General Materials and construction Design Performance requirements General Bacterial filtration efficiency (E Breathability Splash resistance Microbial cleanliness (Bioburd Biocompatibility	
iew o	5.2.7	Summary of performance requ	
Prev	6	Marking, labelling and packaging	
- 61		A (informative) Information for	
LNAS-EN 14683:2019	Annex	B (normative) Method for <i>in vit</i> (BFE)	
146	<b>B.1</b>	General	
EN	<b>B.2</b>	Principle	
NAS	<b>B.3</b>	Reagents and materials	
П	B.3.1	General	
	B.3.2	Tryptic soy agar	
	B.3.3	Tryptic soy broth	
	B.3.4	Peptone water	
	B.3.5	Culture of Staphylococcus aure	

<b>Contents</b> Page				
European foreword4				
Introd	luction	5		
1	Scope	6		
2	Normative references	6		
3	Terms and definitions	6		
4	Classification	8		
5	Requirements			
5.1 5.1.1	General Materials and construction	_		
5.1.2	Design	8		
5.2 5.2.1	Performance requirementsGeneral			
5.2.1 5.2.2	Bacterial filtration efficiency (BFE)			
5.2.3	Breathability	8		
5.2.4 5.2.5	Splash resistanceMicrobial cleanliness (Bioburden)			
5.2.6	Biocompatibility	9		
5.2.7	Summary of performance requirements			
6	Marking, labelling and packaging			
Annex A (informative) Information for users				
Annex	B (normative) Method for <i>in vitro</i> determination of bacterial filtration efficiency (BFE)	12		
B.1	General			
B.2	Principle			
B.3	Reagents and materials			
B.3.1	General	12		
B.3.2	Tryptic soy agar	12		
B.3.3	Tryptic soy broth	12		
<b>B.3.4</b>	Peptone water	13		
B.3.5	Culture of Staphylococcus aureus ATCC 6538, growing on tryptic soy agar slants	13		
<b>B.4</b>	Test apparatus	13		
<b>B.4.1</b>	Six stage cascade impactor, the arrangement is specified in Table B.1.	13		
B.4.2	Nebulizer, capable of delivering particles with a mean size of (3,0 $\pm$ 0,3) $\mu$ m when in contact with the cascade impactor.	13		
B.4.3	Aerosol chamber, glass, 600 mm long and 80 mm in external diameter	13		
<b>B.4.4</b>	Flow meters, capable of measuring a flow rate of 28,3 l/min	13		
B.4.5	Pressure gauge, capable of measuring a pressure of 35 kPa to an accuracy of ± 1 kPa.	13		

<b>B.4.6</b>	Erlenmeyer flasks, 250 ml and 500 ml capacity	13
B.4.7	Peristaltic or syringe pump, capable of delivering 0,01 ml/min	13
<b>B.4.8</b>	Vacuum pump, capable of maintaining a flow rate of 57 l/min	13
B.5	Test specimens	13
B.6	Preparation of bacterial challenge	13
B.7	Procedure	14
<b>B.8</b>	Calculation of bacterial filtration efficiency (BFE)	16
B.9	Test report	16
Annex	C (normative) Method for determination of breathability (differential pressure)	18
<b>C.1</b>	Principle	18
<b>C.2</b>	Test apparatus	19
C.2.1	Mass flow meter(s) capable of measuring an airflow of 8 l/min	19
C.2.2	Manometer, a differential manometer (water or digital). Individual manometers can also be used. M1 is for the upstream pressure measurement and M2 is for the downstream pressure measurement	19
C.2.3	Electric vacuum pump including a pressure buffer tank	
C.2.4	Valve permitting the adjustment of the flow rate	
C.2.5	Sample holder	
<b>C.3</b>	Test specimens	
<b>C.4</b>	Procedure	20
<b>C.5</b>	Calculation of differential pressure	20
<b>C.6</b>	Test report	20
Annex	D (informative) Microbial cleanliness	21
D.1	Sampling	21
<b>D.2</b>	Testing	21
Annex	ZA (informative) Relationship between this European Standard and the essential requirements of Directive 93/42/EEC [1993 OJ L 169] aimed to be covered	22
Riblio	granhy	23

## **European foreword**

This document (EN 14683:2019) has been prepared by Technical Committee CEN/TC 205 "Non-active medical devices", the secretariat of which is held by DIN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by September 2019, and conflicting national standards shall be withdrawn at the latest by September 2019.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

This document supersedes EN 14683:2014.

This document has been prepared under a standardization request given to CEN by the European Commission and the European Free Trade Association, and supports essential requirements of EU Directive(s).

For relationship with EU Directive(s), see informative Annex ZA, which is an integral part of this document.

The main changes compared to the previous edition are:

a) the appropriate method for *in vitro* determination of bacterial filtration efficiency (BFE) provided in Annex B has been updated;

b) the former deleted note in 5.2.3 on the breathability requirements has been reintroduced as standard text; it provides a recommendation regarding the use of a respiratory protective device;

c) the performance requirements on the breathability (differential pressure) provided in Table 1 have been increased and the appropriate method for determination provided in Annex C has been completely reviewed;

d) the determination of the microbial cleanliness (bioburden) has been slightly updated and moved from 5.2.5 to a new informative Annex D.

According to the CEN-CENELEC Internal Regulations, the national standards organisations of the

According to the CEN-CENELEC Internal Regulations, the national standards organisations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Former Yugoslav Republic of Macedonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

### Introduction

The transmission of infective agents during surgical procedures in operating theatres and other medical settings can occur in several ways. Sources are, for example, the noses and mouths of members of the surgical team. The main intended use of medical face masks is to protect the patient from infective agents and, additionally, in certain circumstances to protect the wearer against splashes of potentially contaminated liquids. Medical face masks may also be intended to be worn by patients and other persons to reduce the risk of spread of infections, particularly in epidemic or pandemic situations.

### 1 Scope

This document specifies construction, design, performance requirements and test methods for medical face masks intended to limit the transmission of infective agents from staff to patients during surgical procedures and other medical settings with similar requirements. A medical face mask with an appropriate microbial barrier can also be effective in reducing the emission of infective agents from the nose and mouth of an asymptomatic carrier or a patient with clinical symptoms.

This European Standard is not applicable to masks intended exclusively for the personal protection of staff.

- NOTE 1 Standards for masks for use as respiratory personal protective equipment are available.
- NOTE 2 Annex A provides information for the users of medical face masks.

#### 2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

EN ISO 10993-1:2009, Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process (ISO 10993-1:2009)

EN ISO 11737-1:2018, Sterilization of health care products — Microbiological methods — Part 1: Determination of a population of microorganisms on products (ISO 11737-1:2018)

ISO 22609:2004, Clothing for protection against infectious agents — Medical face masks — Test method for resistance against penetration by synthetic blood (fixed volume, horizontally projected)

#### 3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- IEC Electropedia: available at http://www.electropedia.org/
- ISO Online browsing platform: available at http://www.iso.org/obp

#### 3.1

#### aerosol

gaseous suspension of solid and/or liquid particles

#### 3.2

#### bacterial filtration efficiency

#### **BFE**

efficiency of the medical face mask material(s) as a barrier to bacterial penetration

Note 1 to entry: The BFE test method is used to measure the bacterial filtration efficiency (BFE) of medical face mask materials.

#### 3.3

#### biocompatibility

quality of being accepted in a specific living environment without adverse or unwanted side effects